ZEN Graphene Solutions Ltd (ZTEK) - Total Liabilities
Based on the latest financial reports, ZEN Graphene Solutions Ltd (ZTEK) has total liabilities worth $5.18 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ZEN Graphene Solutions Ltd cash flow conversion to assess how effectively this company generates cash.
ZEN Graphene Solutions Ltd - Total Liabilities Trend (2010–2025)
This chart illustrates how ZEN Graphene Solutions Ltd's total liabilities have evolved over time, based on quarterly financial data. Check ZTEK cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
ZEN Graphene Solutions Ltd Competitors by Total Liabilities
The table below lists competitors of ZEN Graphene Solutions Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
biote Corp
NASDAQ:BTMD
|
USA | $158.01 Million |
|
Falcon Machine Tools Co Ltd
TWO:4513
|
Taiwan | NT$2.94 Billion |
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
USA | $21.24 Million |
|
ImmuCell Corporation
NASDAQ:ICCC
|
USA | $15.93 Million |
|
Shinih Enterprise Co Ltd
TW:9944
|
Taiwan | NT$2.35 Billion |
|
Tunas Alfin Tbk
JK:TALF
|
Indonesia | Rp583.40 Billion |
|
Sonel S.A.
WAR:SON
|
Poland | zł27.03 Million |
|
IBKS No2 SPAC
KQ:204840
|
Korea | ₩26.45 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down ZEN Graphene Solutions Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is ZEN Graphene Solutions Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ZEN Graphene Solutions Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ZEN Graphene Solutions Ltd (2010–2025)
The table below shows the annual total liabilities of ZEN Graphene Solutions Ltd from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $3.65 Million | +104.82% |
| 2024-03-31 | $1.78 Million | -38.70% |
| 2023-03-31 | $2.90 Million | +5.79% |
| 2022-03-31 | $2.75 Million | -1.52% |
| 2021-03-31 | $2.79 Million | +428.46% |
| 2020-03-31 | $527.58K | -18.41% |
| 2019-03-31 | $646.64K | +325.32% |
| 2018-03-31 | $152.03K | +82.52% |
| 2017-03-31 | $83.30K | -8.50% |
| 2016-03-31 | $91.04K | -49.68% |
| 2015-03-31 | $180.92K | -33.57% |
| 2014-03-31 | $272.33K | -45.59% |
| 2013-03-31 | $500.56K | -51.69% |
| 2012-03-31 | $1.04 Million | +2.43% |
| 2011-03-31 | $1.01 Million | +548.91% |
| 2010-03-31 | $155.90K | -- |
About ZEN Graphene Solutions Ltd
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coatings under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It also… Read more